Shravya R Pothula, Miguel Regueiro, Benjamin H Click
{"title":"Advancements in the prevention and management of postoperative Crohn's disease recurrence.","authors":"Shravya R Pothula, Miguel Regueiro, Benjamin H Click","doi":"10.1080/17474124.2025.2514721","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Postoperative recurrence of Crohn's disease after surgery remains common. The aim of this article is to present a comprehensive review of recent advancements in postoperative prognostication, surveillance, and the therapeutic prophylaxis.</p><p><strong>Areas covered: </strong>Reduction in postoperative recurrence risk is a multifactorial process requiring risk stratification, prophylactic therapeutics, and postoperative monitoring. Recent studies have explored the clinical utility of risk stratification paradigms. There are many ongoing trials including SOPRANO-CD which aims to evaluate and compare postoperative medical prophylaxis to endoscopy-driven management and POMEROL to determine optimal management strategy for moderate endoscopic disease activity. Postoperative disease activity monitoring including intestinal ultrasound, fecal calprotectin, and cross-sectional enterography offer a cost-effective and noninvasive alternative to ileocolonoscopy with new guideline recommendations for fecal calprotectin in the postoperative period. Data is emerging on outcomes between postoperative prophylactic versus endoscopy driven management algorithms. Tissue transcriptomics and serum proteomics provide a noninvasive surrogate measure of disease activity by detecting biomarkers of inflammation.</p><p><strong>Expert opinion: </strong>Through the advancements in risk stratification, monitoring modalities and algorithms, and postoperative therapeutics, there is reduction in the rate of postoperative Crohn's recurrence.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1-13"},"PeriodicalIF":3.8000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2025.2514721","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Postoperative recurrence of Crohn's disease after surgery remains common. The aim of this article is to present a comprehensive review of recent advancements in postoperative prognostication, surveillance, and the therapeutic prophylaxis.
Areas covered: Reduction in postoperative recurrence risk is a multifactorial process requiring risk stratification, prophylactic therapeutics, and postoperative monitoring. Recent studies have explored the clinical utility of risk stratification paradigms. There are many ongoing trials including SOPRANO-CD which aims to evaluate and compare postoperative medical prophylaxis to endoscopy-driven management and POMEROL to determine optimal management strategy for moderate endoscopic disease activity. Postoperative disease activity monitoring including intestinal ultrasound, fecal calprotectin, and cross-sectional enterography offer a cost-effective and noninvasive alternative to ileocolonoscopy with new guideline recommendations for fecal calprotectin in the postoperative period. Data is emerging on outcomes between postoperative prophylactic versus endoscopy driven management algorithms. Tissue transcriptomics and serum proteomics provide a noninvasive surrogate measure of disease activity by detecting biomarkers of inflammation.
Expert opinion: Through the advancements in risk stratification, monitoring modalities and algorithms, and postoperative therapeutics, there is reduction in the rate of postoperative Crohn's recurrence.
期刊介绍:
The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.